Literature DB >> 3834835

Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

T E Jones, R W Milne, Y Mudaliar, L N Sansom.   

Abstract

Moxalactam kinetics during continuous ambulatory peritoneal dialysis (CAPD) was followed in eight patients after a single intraperitoneal dose of 1 g. Approximately 60% of the dose was absorbed after a dwell time of 4 h. Dialysis solutions were exchanged at 4-h intervals with an overnight dwell of 8 h. The mean (+/- standard deviation) elimination half-life was 13.2 +/- 2.9 h, and the mean apparent volume of distribution was 0.22 +/- 0.08 liters/kg. Mean total clearance was 11.5 +/- 2.4 ml/min, with a mean dialysis clearance of 2.3 +/- 0.5 ml/min. The maximum concentration in plasma ranged from 24.5 to 54.1 micrograms/ml. Moxalactam concentrations in the peritoneal dialysis fluid were above 80 micrograms/ml during the first exchange and above 2 micrograms/ml for a further three exchanges. A suggested intraperitoneal dose regimen for patients undergoing CAPD is 1 g initially, followed by 15 to 25% of the recommended dose for normal patients given at the same time intervals, or 30 to 50% of the recommended dose at twice the usual intervals. Moxalactam is suggested for initial treatment of peritonitis in CAPD patients who do not have ready access to the antibiotic of choice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3834835      PMCID: PMC180234          DOI: 10.1128/AAC.28.2.293

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

2.  The pharmacokinetics of moxalactam in renal failure.

Authors:  N Wright; P J Wills; R Wise
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

3.  Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography.

Authors:  W F Diven; B D Obermeyer; R L Wolen; V L Yu; J Lyon; J Zuravleff
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

4.  Biliary excretion of moxalactam.

Authors:  O V Martinez; J U Levi; A Livingstone; T I Malinin; R Zeppa; D Hutson; N Einhorn
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

5.  Moxalactam kinetics in hemodialysis.

Authors:  E J Jacobson; J J Zahrowski; A R Nissenson
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

6.  Pharmacokinetics of moxalactam in patients with normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan; F C Luft
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

7.  Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.

Authors:  L R Peterson; B Bean; C E Fasching; W P Korchik; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

8.  High-performance liquid chromatographic analysis of a new beta-lactam antibiotic, 6059-S (moxalactam).

Authors:  R Konaka; K Kuruma; R Nishimura; Y Kimura; T Yoshida
Journal:  J Chromatogr       Date:  1981-09-11

9.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

10.  Moxalactam pharmacokinetics during hemodialysis.

Authors:  G R Aronoff; R S Sloan; S A Mong; F C Luft; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more
  1 in total

1.  Structural insights into sequence-dependent Holliday junction resolution by the chloroplast resolvase MOC1.

Authors:  Junjie Yan; Sixing Hong; Zeyuan Guan; Wenjing He; Delin Zhang; Ping Yin
Journal:  Nat Commun       Date:  2020-03-17       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.